C4 Therapeutics "Buy" On Cemsidomide Advancement And Competitor's Positive Readout

2026-06-02 10:58:12 ET

I'm initiating C4 Therapeutics ( CCCC ) with a "Buy" rating. The reason why I'm doing so is because the company has made significant progress expanding its lead next-generation cereblon E3 ligase modulator [CELMoD] or molecular glue degrader cemsidomide for the treatment of patients with relapsed/refractory multiple myeloma [r/r MM]. Specifically, its lead program involves the development of its oral IKZF1/3 degrader [CELMoD] cemsidomide in combination with dexamethasone to treat patients with 4th-line+ r/r MM in the ongoing phase 2 MOMENTUM single-arm, open-label study. The first patient was dosed for this mid-stage trial in February of 2026, and enrollment completion is expected by Q1 of 2027. From there, if trial recruitment goes well, then the company expects to release initial overall response rate [ORR] data from it in the 2nd half of 2027. ...

Read the full article on Seeking Alpha

For further details see: